来那度胺治疗血液系统恶性肿瘤患者中的第二原发恶性肿瘤:系统综述与荟萃分析
该系统综述与荟萃分析纳入38项随机对照试验共14058例患者,评估来那度胺使用与第二原发恶性肿瘤(SPM)的风险。总体RR为1.16(95%CI 0.96-1.39),但存在适应症间异质性(p=0.020);多发性骨髓瘤RR为1.42(95%CI 1.09-1.84),淋巴瘤或慢性淋巴细胞白血病及骨髓增生异常综合征未见升高。作者认为来那度胺诱导的SPM似乎仅见于多发性骨髓瘤患者。
要点
- 来那度胺治疗多发性骨髓瘤患者SPM风险升高,RR 1.42(95%CI 1.09-1.84)。
- 淋巴瘤或慢性淋巴细胞白血病及骨髓增生异常综合征未见SPM升高。
- 多发性骨髓瘤中,无论是否接受移植,来那度胺均增加实体瘤和血液系统SPM。
核心结论
- 基于当前数据,来那度胺诱导的SPM似乎仅见于多发性骨髓瘤患者。
- 来那度胺可用于其他适应症而无需主要担心治疗相关肿瘤。
- 在多发性骨髓瘤中,来那度胺是有效药物,但患者应监测血液系统和实体瘤SPM,包括未接受自体造血干细胞移植的患者。
- 需要进一步研究以增进对来那度胺仅在多发性骨髓瘤患者中促进SPM的原因的理解。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、CENTRAL、Europe PubMed Central和ClinicalTrials.gov,时间从2004年1月1日至2022年3月18日。
- 纳入至少有一个来那度胺组和一个非来那度胺组的随机对照试验,不限疾病背景,排除中位随访小于12个月的研究。
- 共纳入38项试验、14058例患者,其中18项为多发性骨髓瘤。
- 采用随机效应模型评估SPM的风险比(RR),多发性骨髓瘤研究的分层荟萃分析采用固定效应模型。
- 使用PROTECT工具评估偏倚风险,研究注册于PROSPERO,CRD42021257508。
主要发现
- 全部恶性肿瘤的RR为1.16(95%CI 0.96-1.39)。
- 不同适应症间存在异质性(p=0.020)。
- 多发性骨髓瘤的RR为1.42(95%CI 1.09-1.84)。
- 淋巴瘤或慢性淋巴细胞白血病试验中SPM未增加,RR为0.90(95%CI 0.76-1.08)。
- 骨髓增生异常综合征试验中SPM未增加,RR为0.96(95%CI 0.23-3.97)。
临床怎么用
- 作者认为,来那度胺可用于其他适应症而无需主要担心治疗相关肿瘤。
- 作者认为,在多发性骨髓瘤中,患者应监测血液系统和实体瘤SPM,包括未接受自体造血干细胞移植的患者。
- 作者建议进一步研究以增进对来那度胺仅在多发性骨髓瘤患者中促进SPM的原因的理解。
局限性
- 不同适应症间存在异质性(p=0.020)。
- 需要进一步研究以增进对来那度胺仅在多发性骨髓瘤患者中促进SPM的原因的理解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lenalidomide has been standard therapy for multiple myeloma and other haematological malignancies for more than a decade. Previous meta-analyses identified an association between lenalidomide and second primary malignancies (SPM) in patients with multiple myeloma. However, newer randomised controlled trials using lenalidomide for other indications have not reported an increased incidence of SPM. The aim of this study was to investigate the risk of developing SPM with lenalidomide use in all disease settings. METHODS: We did a systematic review of randomised controlled trials that reported SPM in patients treated with lenalidomide. PubMed, Embase, CENTRAL, Europe PubMed Central, and ClinicalTrials.gov were searched from Jan 1, 2004, to March 18, 2022. Randomised controlled trials with at least one lenalidomide group and one non-lenalidomide group were selected, regardless of the disease setting. Studies with a median follow-up of less than 12 months were excluded. Summary data were extracted by two reviewers (KS and KL) independently and verified by a third reviewer (JF). We then conducted a meta-analysis to assess the risk ratio (RR) of SPM with lenalidomide use across various disease subtypes using a random-effects model. We chose random effects for the primary analysis because of anticipated heterogeneity between different diseases, but we used fixed effects for stratified meta-analysis of multiple myeloma studies. Risk of bias was assessed with the PROTECT tool. The study was registered with PROSPERO, CRD42021257508. FINDINGS: Our search yielded 9078 studies, and 38 trials that included 14 058 patients were eligible for meta-analysis after screening, 18 of which were in multiple myeloma. The RR across all malignancies was 1·16 (95% CI 0·96-1·39). However, there was heterogeneity across indications (p=0·020). The RR when lenalidomide was used for multiple myeloma was 1·42 (1·09-1·84). There was no increase in SPM in lymphoma or chronic lymphocytic leukaemia (0·90 [0·76-1·08]) and myelodysplastic syndrome (0·96 [0·23-3·97]) trials. In the setting of multiple myeloma, lenalidomide increased both solid and haematological SPM, both in the no-transplantation and post-transplantation settings. From the 38 trials, 21 (55%) had low risk of bias, 12 (32%) had unclear risk of bias, and five (13%) had high risk of bias. INTERPRETATION: Based on the current data, lenalidomide-induced SPM seem to occur exclusively in patients with multiple myeloma. Thus, lenalidomide can be used for other indications without the major concern of a therapy-related neoplasm. In the multiple myeloma setting, lenalidomide is an effective drug, but patients should be monitored both for haematological and solid tumour SPM. This monitoring includes patients that have not received autologous haematopoietic stem-cell transplantation. Further investigations are needed to improve understanding on why lenalidomide only promotes SPM in patients with multiple myeloma. FUNDING: None.
引用
- Saleem K, Franz J, Klem ML, et al. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. Lancet Haematol. 2022. PMID: 36354020. doi:10.1016/S2352-3026(22)00289-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。